Accuitis, Inc.

2:45 PM - 3:00 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Accuitis, Inc. is a US registered company with located in Peachtree Corners, GA. We are engaged in the development and formulation of dermatological & ophthalmic pharmaceuticals targeting niche, orphan, and under served indications.
ADU-D1: Our lead discovery compound inhibits the transcription factor, nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation. NFkB has already been shown to be a major, if not the major mediator of skin & ocular diseases including Rosacea. ACU-D1 have completed a Phase sucessful 2A clinical study in healthy patients with rosacea (sub-type 2) & anticipate advancing into phase 2B dose ranging studies in 2019.
Honokiol Hexafluoro (ACU-D2); is a preclinical platform technology also discovered at Emory University. We have discovered that this compound is a Sirt 3 agonist and has potential in several unmet/under met clinical needs such as Systemic Scleroderma (SSc), Psoriasis, Retinopathy of Prematurity, and Diabetic Retinopathy
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ACU-D1 Proteasome Inhibitor Sub -Type 2 Rosacea
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):